From Surface Oncology Raises $35M to Develop Cancer Immunotherapies:

Dave Grayzel, Atlas Venture partner and acting CEO, Surface Oncology
Dave Grayzel, Atlas Venture partner and acting CEO, Surface Oncology

Dave Grayzel, Atlas Venture partner and acting CEO, Surface Oncology